interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Gallium Ga-68 Gozetotide

Generic competition · all medicines · read 12 November 2026

Is there a generic of Gallium Ga-68 Gozetotide, and who makes it?

Gallium Ga-68 Gozetotide appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 2 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 5.4 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Gallium Ga-68 Gozetotide2 dosage-form groups in the Orange Book
2generic makers listed
  1. Gallium Ga-68 Gozetotide appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 2 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 5.4 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Intravenous

One to three generic makers listed

Brand listed as marketed: Gallium Ga 68 Gozetotide. 2 generic makers with 2 generic products listed as marketed; the first generic approval is dated 14 May 2026.

20202025203002brand 2020Ionetix Corp, first approval 14 May 2026Radiomedix Inc, first approval 8 June 2026data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Ionetix Corp14 May 20261
Radiomedix Inc8 June 20261

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Powder, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Gozellix, Illuccix and Locametz. No generic is listed as marketed.

2020202520302035204001brand 2021data datePatent 11369590 listed to expire 15 August 2028Patent 11027031 listed to expire 28 July 2035Patent 12109277 listed to expire 9 March 2036
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 15 August 2028Patent 11369590 drug substance
  • 28 July 2035Patent 11027031
  • 9 March 2036Patent 12109277

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.